1. Home
  2. ZKH vs OCGN Comparison

ZKH vs OCGN Comparison

Compare ZKH & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ZKH Group Limited

ZKH

ZKH Group Limited

HOLD

Current Price

$2.90

Market Cap

465.1M

Sector

N/A

ML Signal

HOLD

Logo Ocugen Inc.

OCGN

Ocugen Inc.

HOLD

Current Price

$1.06

Market Cap

474.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZKH
OCGN
Founded
1998
2013
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
465.1M
474.8M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
ZKH
OCGN
Price
$2.90
$1.06
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.75
AVG Volume (30 Days)
343.2K
6.7M
Earning Date
05-19-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$9.02
N/A
Revenue Next Year
$10.41
$1,718.38
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.92
$0.97
52 Week High
$3.90
$2.73

Technical Indicators

Market Signals
Indicator
ZKH
OCGN
Relative Strength Index (RSI) 45.31 35.90
Support Level $2.50 N/A
Resistance Level $3.00 $1.93
Average True Range (ATR) 0.09 0.08
MACD -0.01 -0.03
Stochastic Oscillator 43.14 20.73

Price Performance

Historical Comparison
ZKH
OCGN

About ZKH ZKH Group Limited

ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. Majority of the revenues are derived from the PRC.

About OCGN Ocugen Inc.

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Share on Social Networks: